16:20 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Cell culture studies suggest inhibiting VCIP135 could help treat botulism. An siRNA screen in an HEK cell-based model of botulism-associated neurotoxicity involving the light chain of Clostridium botulinum toxin type A showed knockdown...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

RT001: Interim Phase II data

Interim data from a double-blind, U.S. Phase II trial in 67 patients with primary axillary hyperhidrosis showed that a single application of high-dose topical RT001 significantly reduced gravimetrically measured sweat production at week 4 vs....
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

RT001: Phase III started

Revance began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate single doses of topical RT001 applied to both sides of the face in up to 450 patients with moderate to severe lateral canthal lines....
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Evosyal: Completed Phase III enrollment

Strathspey’s Alphaeon subsidiary completed enrollment in a pair of double-blind, placebo-controlled, U.S. Phase III trials evaluating injections of Evolus. The trials were each targeting 324 patients. Alphaeon gained exclusive rights to market Evolus in the...
08:00 , Mar 8, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Clostridium Clostridium botulinum toxin type A; botulinum neurotoxin type A1 nontoxic-nonhemagglutinin component (ntnH) Structural and in vitro studies suggest inhibiting binding between C. botulinum...
08:00 , Mar 8, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune Disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Indoleamine 2, 3-dioxygenase (INDO; IDO) Mouse studies suggest IDO could help treat and prevent autoimmune diseases. In lupus-prone mice, an IDO inhibitor...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Xoma infectious news

Xoma received a five-year contract worth up to $28 million from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop antitoxins to treat Type C and D botulism poisoning. Xoma has received about...
07:00 , May 9, 2011 |  BC Week In Review  |  Clinical News

XOMA 3AB: Phase I started

Xoma said NIH's National Institute of Allergy and Infectious Diseases (NIAID) began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single doses of XOMA 3AB in about 24 healthy volunteers. Xoma Ltd. (NASDAQ:XOMA),...
08:00 , Feb 24, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Clostridium; ebola; malaria Clostridium botulinum toxin type A In vitro and mouse studies identified 1,7-bis(aminoalkyl)diazachrysene-based derivatives that could help treat...